Cargando…
Are the COVID-19’s vaccines efficient on the most dangerous variant of SARS-CoV-2?
Autores principales: | Davoodi, Poorya, Hashemi, Atousa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Vaccine Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511588/ https://www.ncbi.nlm.nih.gov/pubmed/34703817 http://dx.doi.org/10.7774/cevr.2021.10.3.301 |
Ejemplares similares
-
SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants
por: Syahniar, Rike, et al.
Publicado: (2022) -
SARS-CoV-2 vaccine-related neurological complications
por: Oonk, Nicol G. M., et al.
Publicado: (2022) -
Neurological Complications of SARS-CoV, MERS-CoV, and COVID-19
por: Alshebri, Munirah Saad, et al.
Publicado: (2020) -
Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults
por: Jo, Juandy, et al.
Publicado: (2022) -
Viral shedding patterns of symptomatic SARS-CoV-2 infections by periods of variant predominance and vaccination status in Gyeonggi Province, Korea
por: Choi, Gawon, et al.
Publicado: (2022)